OBJECTIVE: Insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) may be important determinants of glucose homeostasis. We examined the association between circulating concentrations of IGF-1, IGFBP-1 in early pregnancy and development of gestational diabetes mellitus (GDM). STUDY DESIGN: Maternal plasma (collected at 13 weeks) IGF-1, IGFBP-1, and C-peptide were measured using immunoassay. Relative risks (RR) and 95% CIs were calculated. RESULTS: The percentage of the cohort that developed GDM was 5.8% (n = 804). Free IGF-1 and IGFBP-1 were inversely associated with GDM risk, while C-peptide was positively associated with GDM risk (P for trend test < .05). Women with free IGF-1 > or = 1.08 ng/mL experienced a 69% reduced risk of GDM (CI 0.12-0.75) compared with women having concentrations < 0.80 ng/mL. There was a 57% reduced risk of GDM among women with IGFBP-1 > or = 68.64 ng/mL (RR = 0.43, CI 0.18-1.05). Women with C-peptide > or = 3.00 ng/mL experienced a 2.28-fold increased risk of GDM (CI 1.00-5.19) compared with women who had concentrations < 1.45 ng/mL. CONCLUSION: These associations may help to further elucidate the pathologic process of GDM.
OBJECTIVE:Insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) may be important determinants of glucose homeostasis. We examined the association between circulating concentrations of IGF-1, IGFBP-1 in early pregnancy and development of gestational diabetes mellitus (GDM). STUDY DESIGN: Maternal plasma (collected at 13 weeks) IGF-1, IGFBP-1, and C-peptide were measured using immunoassay. Relative risks (RR) and 95% CIs were calculated. RESULTS: The percentage of the cohort that developed GDM was 5.8% (n = 804). Free IGF-1 and IGFBP-1 were inversely associated with GDM risk, while C-peptide was positively associated with GDM risk (P for trend test < .05). Women with free IGF-1 > or = 1.08 ng/mL experienced a 69% reduced risk of GDM (CI 0.12-0.75) compared with women having concentrations < 0.80 ng/mL. There was a 57% reduced risk of GDM among women with IGFBP-1 > or = 68.64 ng/mL (RR = 0.43, CI 0.18-1.05). Women with C-peptide > or = 3.00 ng/mL experienced a 2.28-fold increased risk of GDM (CI 1.00-5.19) compared with women who had concentrations < 1.45 ng/mL. CONCLUSION: These associations may help to further elucidate the pathologic process of GDM.
Authors: Emily Oken; Emma Morton-Eggleston; Sheryl L Rifas-Shiman; Karen M Switkowski; Marie-France Hivert; Abby F Fleisch; Christos Mantzoros; Matthew W Gillman Journal: Am J Perinatol Date: 2016-08-04 Impact factor: 1.862
Authors: Swapnil N Rajpathak; Aileen P McGinn; Howard D Strickler; Thomas E Rohan; Michael Pollak; Anne R Cappola; Lewis Kuller; XiaoNan Xue; Anne B Newman; Elsa S Strotmeyer; Bruce M Psaty; Robert C Kaplan Journal: Growth Horm IGF Res Date: 2007-09-27 Impact factor: 2.372
Authors: Erin S LeBlanc; Ning X Smith; Kimberly K Vesco; Teresa A Hillier; Victor J Stevens Journal: J Clin Endocrinol Metab Date: 2021-11-19 Impact factor: 6.134